U.S. markets open in 4 hours 36 minutes
  • S&P Futures

    4,243.25
    -3.25 (-0.08%)
     
  • Dow Futures

    34,216.00
    -72.00 (-0.21%)
     
  • Nasdaq Futures

    14,043.00
    +12.75 (+0.09%)
     
  • Russell 2000 Futures

    2,311.20
    -4.50 (-0.19%)
     
  • Crude Oil

    72.23
    +0.11 (+0.15%)
     
  • Gold

    1,861.20
    +4.80 (+0.26%)
     
  • Silver

    27.89
    +0.20 (+0.71%)
     
  • EUR/USD

    1.2132
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4990
    0.0000 (0.00%)
     
  • Vix

    17.28
    +0.89 (+5.43%)
     
  • GBP/USD

    1.4107
    +0.0025 (+0.18%)
     
  • USD/JPY

    109.9400
    -0.0940 (-0.09%)
     
  • BTC-USD

    40,056.85
    +302.17 (+0.76%)
     
  • CMC Crypto 200

    997.08
    -13.53 (-1.34%)
     
  • FTSE 100

    7,173.63
    +1.15 (+0.02%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

HOUSTON, March 15, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m. ET.

Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)

A live webcast of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-oppenheimer-31st-annual-healthcare-conference-301246974.html

SOURCE Marker Therapeutics, Inc.